TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low/HER2-breast cancer

被引：0
|
作者：
McArthur, Heather
Tolaney, Sara
Loibl, Sibylle
Dent, Rebecca
Schmid, Peter
Asselah, Jamil
Song, Erwei
Niikura, Naoki
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-20-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-20-13
引用
收藏
页数：3
相关论文
共 36 条
  • [1] TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2-breast cancer
    Mcarthur, Heather L.
    Tolaney, Sara M.
    Dent, Rebecca
    Schmid, Peter
    Asselah, Jamil
    Liu, Qiang
    Meisel, Jane Lowe
    Niikura, Naoki
    Park, Yeon Hee
    Werutsky, Gustavo
    Bianchini, Giampaolo
    Andersen, Jay C.
    Kozarski, Robert
    Rokutanda, Nana
    Pistilli, Barbara
    Loibl, Sibylle
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [2] TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
    Bardia, A.
    Pusztai, L.
    Albain, K.
    Kalinsky, K.
    Hershman, D.
    Barlow, W.
    Tokunaga, E.
    Ciruelos, E. M.
    Loirat, D.
    Isaacs, C.
    Testa, L.
    Dry, H.
    Kozarski, R.
    Maxwell, M.
    Harbeck, N.
    Sharma, P.
    BREAST, 2023, 68 : S23 - S23
  • [3] Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy in previouslytreated, inoperable or metastatic HR+/HER2-breast cancer: TROPION-Breast01
    Bardia, Aditya
    Kalinsky, Kevin
    Tsurutani, Junji
    Hamilton, Erika
    Sohn, Joo Hyuk
    Park, Kyong Hwa
    Park, Yeon Hee
    Im, Seock-Ah
    Lee, Keun Seok
    Dastur, Daisy
    Haddad, Vincent
    Khan, Sabrina
    Xu, Binghe
    Pistilli, Barbara
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer (BC)
    Meric-Bernstam, Funda
    Krop, Ian
    Juric, Dejan
    Kogawa, Takahiro
    Hamilton, Erika
    Spira, Alexander I.
    Mukohara, Toru
    Tsunoda, Takuya
    Damodaran, Senthil
    Greenberg, Jonathan
    Gu, Wen
    Kobayashi, Fumiaki
    Zebger-Gong, Hong
    Kawasaki, Yui
    Wong, Rie
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study
    Schmid, P.
    Jung, K. H.
    Wysocki, P. J.
    Jassem, J.
    Ma, C. X.
    Fernandes, R.
    Huisden, R.
    Stewart, R.
    Vukovic, P.
    Nunes, A. Tablante
    Nowecki, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S199 - S199
  • [6] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
    Schmid, P.
    Wysocki, P. J.
    Ma, C. X.
    Park, H.
    Fernandes, R.
    Lord, S.
    Baird, R. D.
    Prady, C.
    Jung, K. H.
    Asselah, J.
    Huisden, R.
    Stewart, R.
    Heider, K.
    Vukovic, P.
    Denduluri, N.
    Nowecki, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S337 - S337
  • [7] Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study
    Schmid, Peter
    Wysocki, Piotr
    Ma, Cynthia
    Park, Yeon H.
    Fernandes, Ricardo
    Lord, Simon
    Baird, Richard D.
    Prady, Catherine
    Jung, Kyung Hae
    Asselah, Jamil
    Huisden, Robert
    Stewart, Ross
    Vukovic, Petra
    Nunes, Ana T.
    Nowecki, Zbigniew
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
    Bardia, A.
    Jhaveri, K.
    Im, S. A.
    Simon, S. Pernas
    De laurentiis, M.
    Wang, S.
    Martinez, N.
    Borges, G. Santos
    Cescon, D. W.
    Hattori, M.
    Lu, Y. S.
    Hamilton, E. P.
    Zhang, Q. Y.
    Tsurutani, J.
    Kalinsky, K.
    Xu, L.
    Denduluri, N.
    Rugo, H. S.
    Xu, B.
    Pistilli, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1264 - S1265
  • [9] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study
    Pernas, Sonia
    Im, Seock-Ah
    Hattori, Masaya
    Xu, Binghe
    Wang, Shusen
    Lu, Yen-Shen
    Borges, Giuliano
    Tsurutani, Junji
    Jhaveri, Komal L.
    Zhang, Qingyuan
    De laurentiis, Michelino
    Martinez-Janez, Noelia
    Hamilton, Erika P.
    Rugo, Hope S.
    Kalinsky, Kevin
    Tolaney, Sara M.
    Shi, Lei
    Khan, Sabrina Sharmin
    Zhu, Yanyan
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2-) breast cancer: TROPION-Breast01
    Bardia, A.
    Kalinsky, K.
    Tsurutani, J.
    Hamilton, E. P.
    Johnston, S.
    Sohn, J.
    Park, K. H.
    Park, Y. H.
    Im, S-A.
    Lee, K. S.
    Dastur, D.
    Haddad, V.
    Khan, S.
    Xu, B.
    Pistilli, B.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S663 - S663
1234